Skip to main content
Top
Published in: Diabetologia 9/2006

01-09-2006 | Article

Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling

Authors: W. H. O. Clausen, A. De Gaetano, A. Vølund

Published in: Diabetologia | Issue 9/2006

Login to get access

Abstract

Aims/hypothesis

Pharmacokinetics of s.c. administered insulin preparations have been widely studied, mostly using descriptive measures such as AUC, time to peak, or the peak plasma concentration. Several compartmental modelling studies of single-bolus s.c. insulin pharmacokinetics have also appeared, with contrasting results regarding the feasibility of insulin pharmacokinetics modelling and the appropriate level of detail for such models. In this paper, we used compartmental models to study the pharmacokinetics of biphasic insulin aspart administered by multiple s.c. injections. The main objective was to assess the magnitude of the inter-and intra-subject variation in the kinetics.

Materials and methods

Analyses were performed on 24-h serum insulin concentrations measured in 20 type 1 diabetes subjects given three daily s.c. injections of biphasic insulin aspart.

Results

Preliminary analysis of the AUC:dose ratio showed that the apparent kinetics are not constant throughout the three daily injections of the compound. A simple and robust compartmental model was shown to be appropriate for interpreting the observations, provided that one of its parameters (the first-order rate constant for transfer from the s.c. depot to plasma) is allowed to vary between injections.

Conclusions/interpretation

Population estimates of the chosen model show that intra-subject variations between injections is of the same order of magnitude as inter-subject variation, partially explaining the difficulties encountered when individually tailoring intensified insulin therapy. We conclude that the explicit consideration of a rather simple kinetic model will allow better experimental designs in the future study of s.c. insulin preparations.
Literature
1.
go back to reference The diabetes control and complications trial research group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The diabetes control and complications trial research group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
2.
go back to reference Brange J, Vølund A (1999) Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307–335PubMedCrossRef Brange J, Vølund A (1999) Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307–335PubMedCrossRef
3.
go back to reference Lindholm A, Jacobsen JV (2001) Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 40:641–659PubMedCrossRef Lindholm A, Jacobsen JV (2001) Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 40:641–659PubMedCrossRef
4.
go back to reference Kaku K, Matsuda M, Urae A, Irie S (2000) Pharmacokinetics and pharmacodynamics of insulin aspart a rapid-acting analog of human insulin in healthy Japanese volunteers. Diabet Res Clin Pract 49:119–126CrossRef Kaku K, Matsuda M, Urae A, Irie S (2000) Pharmacokinetics and pharmacodynamics of insulin aspart a rapid-acting analog of human insulin in healthy Japanese volunteers. Diabet Res Clin Pract 49:119–126CrossRef
5.
go back to reference Chen J-W, Lauritsen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS (2005) Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study. Diabet Med 22:273–277PubMedCrossRef Chen J-W, Lauritsen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS (2005) Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study. Diabet Med 22:273–277PubMedCrossRef
6.
go back to reference Brange J, Ribel U, Hansen JF et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679–682PubMedCrossRef Brange J, Ribel U, Hansen JF et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679–682PubMedCrossRef
7.
go back to reference Brange J (1997) The new era of biotech insulin analogues. Diabetologia 40 (Suppl 2):S48–S53CrossRef Brange J (1997) The new era of biotech insulin analogues. Diabetologia 40 (Suppl 2):S48–S53CrossRef
8.
go back to reference Jacobsen LV, Søgaard B, Riis A (2000) Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 56:399–403PubMedCrossRef Jacobsen LV, Søgaard B, Riis A (2000) Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 56:399–403PubMedCrossRef
9.
go back to reference Vølund A, Brange J, Drejer K et al (1991) In vitro and in vivo potency insulin analogues designed for clinical use. Diabet Med 8:839–847PubMedCrossRef Vølund A, Brange J, Drejer K et al (1991) In vitro and in vivo potency insulin analogues designed for clinical use. Diabet Med 8:839–847PubMedCrossRef
10.
go back to reference Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7:188–199PubMedCrossRef Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7:188–199PubMedCrossRef
11.
go back to reference Wenk RE (1998) Mechanism of interference by hemolysis in immunoassays and requirements for sample quality. Clin Chem 44:2554PubMed Wenk RE (1998) Mechanism of interference by hemolysis in immunoassays and requirements for sample quality. Clin Chem 44:2554PubMed
12.
go back to reference Littell RC, Milliken GA, Stroup WW, Wolfinger RD (1996) SAS system for mixed models. Cary, SAS Institute Littell RC, Milliken GA, Stroup WW, Wolfinger RD (1996) SAS system for mixed models. Cary, SAS Institute
13.
go back to reference Clausen WHO, Tabanera R, Dalgaard P (2005) Solving the bias problem in pharmacokinetic data. Research Report 05/05. University of Copenhagen, Denmark Clausen WHO, Tabanera R, Dalgaard P (2005) Solving the bias problem in pharmacokinetic data. Research Report 05/05. University of Copenhagen, Denmark
14.
go back to reference Goldberg DE (1989) Genetic algorithms in search, optimization, and machine learning. Addison-Wesley, Reading Goldberg DE (1989) Genetic algorithms in search, optimization, and machine learning. Addison-Wesley, Reading
15.
go back to reference Bates DM, Watts DG (1988) Nonlinear regression analysis and its applications. Wiley, New York Bates DM, Watts DG (1988) Nonlinear regression analysis and its applications. Wiley, New York
17.
go back to reference Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin’s physiochemical properties—evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:1057–1065PubMedCrossRef Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin’s physiochemical properties—evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:1057–1065PubMedCrossRef
18.
go back to reference Nucci G, Cobelli C (2000) Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed 62:249–257PubMedCrossRef Nucci G, Cobelli C (2000) Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed 62:249–257PubMedCrossRef
19.
go back to reference Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R (2005) Insulin kinetics in type 1 diabetes. Continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 52:3–12PubMedCrossRef Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R (2005) Insulin kinetics in type 1 diabetes. Continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 52:3–12PubMedCrossRef
20.
go back to reference Kobayashi T, Sawano T, Itoh T, Kosaka K, Hirayama H, Kasuya Y (1983) The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32:331–336PubMedCrossRef Kobayashi T, Sawano T, Itoh T, Kosaka K, Hirayama H, Kasuya Y (1983) The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32:331–336PubMedCrossRef
21.
go back to reference Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67–87PubMedCrossRef Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67–87PubMedCrossRef
22.
go back to reference Robinson RTCE, Harris, ND, Ireland RH, Lindholm A, Heller SR (2003) Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. Br J Clin Pharmacol 55:246–251PubMedCrossRef Robinson RTCE, Harris, ND, Ireland RH, Lindholm A, Heller SR (2003) Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. Br J Clin Pharmacol 55:246–251PubMedCrossRef
23.
go back to reference Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J (2002) Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 25:876–882PubMedCrossRef Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J (2002) Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 25:876–882PubMedCrossRef
24.
go back to reference Heinemann L (2002) Variability of insulin absorption and insulin action. Diabetes Technol Ther 4:673–682PubMedCrossRef Heinemann L (2002) Variability of insulin absorption and insulin action. Diabetes Technol Ther 4:673–682PubMedCrossRef
25.
go back to reference Perriello G, De Feo P, Torlone E et al (1991) The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34:21–28PubMedCrossRef Perriello G, De Feo P, Torlone E et al (1991) The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34:21–28PubMedCrossRef
26.
go back to reference Holl RW, Heinze E (1992) Dawn or Somogyi phenomenon? High morning fasting blood sugar levels in juvenile type 1 diabetics. Deutsche Medizinische Wochenschrift 117:1503–1507 (German)PubMedCrossRef Holl RW, Heinze E (1992) Dawn or Somogyi phenomenon? High morning fasting blood sugar levels in juvenile type 1 diabetics. Deutsche Medizinische Wochenschrift 117:1503–1507 (German)PubMedCrossRef
Metadata
Title
Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling
Authors
W. H. O. Clausen
A. De Gaetano
A. Vølund
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0327-z

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.